Existing horizon scanning activities could be strengthened to aid budget planning in the context of high upfront cost therapies such as gene therapies. International collaborations could be leveraged ...

Meindert is a highly respected expert in the field of Health Technology Assessment (HTA) with more than 25 years’ experience in the field. Before starting as an independent advisor, Meindert was ...

The Office of Health Economics is delighted to host the Health Economists’ Study Group Summer Meeting, which will run from 30th June – 2nd July 2025. Founded in 1972, the Health Economists’ Study ...

Today marks Rare Disease Day 2025. This time last year we published an Article entitled “Why do we care about rare?”, summarising the origins of rare disease day, the fundamental ambition – to strive ...

Measuring and valuing health outcomes is arguably what makes health economics such a unique and sometimes controversial discipline. The idea of putting a numerical value on an individual’s health ...

Hannah joined OHE as an Economist in September 2024. She holds an MPharm degree from the University of Nottingham and an MSc in Health Economics and Health Policy from the University of Birmingham. As ...

Dr Seán Byrne is Senior Manager, Legal & Regulatory Affairs for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Seán represents EUCOPE members at relevant European Medicines ...

Dimitrios is an economist and his research interests lie in the fields of the economics of innovation and specifically on the economics of pharmaceutical markets and R&D. In addition, he is interested ...

Dr. Inmaculada (Inma) Hernandez is a Professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hernandez is a pharmacist and a scholar whose ...

Sukanya joined OHE in August 2024 and is an economist by training. Sukanya has previously worked in medical consulting, where she developed economic models for submission to Health Technology ...